Home Food & Drug Administration (FDA)
HHS/Food & Drug Administration (FDA)
21
May
2002
LDA Remarks Before Vaccines & Related Biological Products Advisory Committee Print E-mail

Why more adverse events were seen after the vaccine reached the market: 
    People receiving Lymerix after product launch lived in Lyme-endemic areas.
Read more...
 
22
Jan
2002
LYMERIX Meeting Print E-mail
SPECIAL REPORT: LDA MEETS WITH FDA ON LYMERIX

On...
Read more...
 
31
Jan
2001
LDA Remarks Before Vaccines & Related Biological Products Advisory Committee Print E-mail
I am here today because we do favor a safe and effective vaccine, but we are unsure whether an OSP A based vaccine can meet those criteria. Since the inception of OSP A vaccine trials, we...
Read more...
 
07
Jul
2000
FDA Public Health Advisory Print E-mail

Assays for Antibodies to Borrelia burgdorferi; Limitations, Use, and Interpretation for Supporting a Clinical Diagnosis of Lyme Disease

July 7, 1997

Purpose
FDA is advising you about the potential for misdiagnosis of Lyme disease. The results of commonly...
Read more...
 

Contact Us

Lyme Disease Association, Inc.
PO Box 1438, Jackson, NJ 08527
888-366-6611 |  information line
732-938-7215 |  fax
LDA@LymeDiseaseAssociation.org | email